Rezatapopt

DB18980InvestigationalSmall molecule

Rezatapopt is under investigation in clinical trial NCT04585750 (The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)).

Mechanism: Pharmacologically active on Cellular tumor antigen p53
Curator reviewed
Formula / weight: C₂₈H₃₁F₄N₅O₂ · 545.583 g/mol (avg)
Also known as: 4-[[3-[4-[[(3S,4R)-3-Fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]-2-propyn-1-yl]amino]-3-methoxy-N-methylbenzamide · Benzamide, 4-[[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]-2-propyn-1-yl]amino]-3-methoxy-N-methyl-
Code names: PC-14586

Resolves to

Compound

UNII5W59S33KC9CAS2636846-41-6

Structure

InChIKeyNKRKBSQLUPEVCZ-JTHBVZDNSA-NSMILESCNC(=O)C1=CC=C(NCC#CC2=CC3=C(N[C@@H]4CCN(C)C[C@@H]4F)C=CC=C3N2CC(F)(F)F)C(OC)=C1

Targets

P04637TP53

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rezatapopt, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account